PROTAC-Mediated Targeting of IKKβ and NR4A1 for AML Therapy
Chandra Kumar Maharjan, Yi Liu, Yufeng Xiao, Bristy Rani Podder, Terri Montgomery, Lei Wang, Myung‐Chul Kim, Zeng Jin, Seyedehalaleh Anvar, Tanzia Islam Tithi, Vivek M. Shastri, Alexandra M. Stevens, Ryan H. Kolb, Chen Zhao, Zhijian Qian, , Weizhou Zhang
This paper identifies IKKβ and NR4A1 as drivers of AML and develops a PROTAC to degrade them, showing potent cytotoxicity and reduced leukemia progression in mice.
Oncogene · Jul 30, 2026Peer-reviewedCancer Biology